Founded in 2018, Fangyuan Capital is a private equity investment firm focused on the life sciences, healthcare, and related fields. Fangyuan Capital actively seeks innovative entrepreneurial teams and explores outstanding companies in segmented markets. Leveraging its abundant industry resources and experience, Fangyuan Capital empowers its portfolio companies with comprehensive support from startup to IPO, accompanying their growth and helping them become outstanding enterprises with high social influence and industry status. Currently, Fangyuan Capital manages two USD funds, one RMB fund, and several single-project funds. Its portfolio includes outstanding enterprises such as Jacobio Pharmaceuticals (1167.HK), XtalPi, Innorna, LePure, and Bluepha.